Our top pick for
US stocks

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
PYC Therapeutics is a biotechnology business based in Australia. PYC Therapeutics shares (PYC) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. PYC Therapeutics has a trailing 12-month revenue of around $9.1 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
52-week range | $0.061 - $0.165 |
---|---|
50-day moving average | $0.0824 |
200-day moving average | $0.1169 |
Target price | $0.02 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.005 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.073
1 month (2022-05-27) | 0.073 |
---|---|
3 months (2022-03-28) | -26.26% |
6 months (2021-12-24) | -47.86% |
1 year (2021-06-28) | -51.33% |
---|---|
2 years (2020-06-26) | -33.64% |
3 years (2019-06-28) | 156.14% |
Revenue TTM | $9.1 million |
---|---|
Gross profit TTM | $3.1 million |
Return on assets TTM | -18.92% |
Return on equity TTM | -31.85% |
Profit margin | -185.43% |
Book value | 0.015 |
Market capitalisation | $254.5 million |
TTM: trailing 12 months
We're not expecting PYC Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, PYC Therapeutics 's shares have ranged in value from as little as $0.061 up to $0.165. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while PYC Therapeutics 's is 0.392. This would suggest that PYC Therapeutics 's shares are less volatile than average (for this exchange).
PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.